TET2Overexpression in Chronic Lymphocytic Leukemia Is Unrelated to the Presence ofTET2Variations
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TET2Overexpression in Chronic Lymphocytic Leukemia Is Unrelated to the Presence ofTET2Variations
Authors
Keywords
-
Journal
Biomed Research International
Volume 2014, Issue -, Pages 1-6
Publisher
Hindawi Limited
Online
2014-02-19
DOI
10.1155/2014/814294
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma
- (2013) F. Asmar et al. HAEMATOLOGICA
- Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling
- (2012) A. E. Rodríguez et al. ANNALS OF ONCOLOGY
- TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis
- (2011) Cyril Quivoron et al. CANCER CELL
- Tet1 Is Dispensable for Maintaining Pluripotency and Its Loss Is Compatible with Embryonic and Postnatal Development
- (2011) Meelad M. Dawlaty et al. Cell Stem Cell
- The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories
- (2011) A Kohlmann et al. LEUKEMIA
- Landscape of TET2 mutations in acute myeloid leukemia
- (2011) S Weissmann et al. LEUKEMIA
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
- (2011) Víctor Quesada et al. NATURE GENETICS
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine
- (2011) S. Ito et al. SCIENCE
- Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
- (2010) A. E. Smith et al. BLOOD
- Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission
- (2010) O. Nibourel et al. BLOOD
- Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
- (2010) Katharina Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
- (2010) Myunggon Ko et al. NATURE
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
- (2009) O. Abdel-Wahab et al. BLOOD
- TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
- (2009) O. Kosmider et al. BLOOD
- Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
- (2009) A. M. Jankowska et al. BLOOD
- A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia
- (2009) J. A. Hernandez et al. HAEMATOLOGICA
- TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
- (2009) O. Kosmider et al. HAEMATOLOGICA
- Acquired mutations in TET2 are common in myelodysplastic syndromes
- (2009) Saskia M C Langemeijer et al. NATURE GENETICS
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started